Literature DB >> 436924

Plasma levels and negative chronotropic effect of metoprolol following single doses of a conventional and sustained-release formulation.

C P Quaterman, M J Kendall, P G Welling.   

Abstract

Plasma levels and associated reduction in exercise-induced tachycardia have been examined following the administration of single doses of metoprolol in conventional and slow-release tablets at different times to six healthy male subjects. The study was carried out in two parts. Initially, the tablets were given at 9 a.m. and the subjects were studied up to 14 h and then at 24 h. Subsequently, the same doses were given at 9 p.m. and the subjects were studied 12-24 h after drug administration (i.e. 9 a.m.-9 p.m. the next day). After giving the slow-release tablets the peak plasma levels were significantly lower but the drug persisted in the plasma at higher levels than after the conventional tablet. However, the beta-blocking effect was comparable from the two dosages. The results obtained for the period 12-24 h after the evening dose differed from the corresponding values after morning administration in that the plasma levels were higher and the beta-blocking effects more marked. Furthermore, the half-life values calculated from these data were significantly longer.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 436924     DOI: 10.1007/bf00609871

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Combined pharmacokinetic and pharmacodynammc studies in man of the adrenergic beta1-receptor antagonist metoprolol.

Authors:  G Johnsson; C G Regårdh; L Sölvell
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

2.  Letter: Daily antihypertensive therapy.

Authors:  M J Kendall; R A Yates
Journal:  Br Med J       Date:  1976-06-05

3.  Per cent absorbed time plots derived from blood level and/or urinary excretion data.

Authors:  J G WAGNER; E NELSON
Journal:  J Pharm Sci       Date:  1963-06       Impact factor: 3.534

4.  Comparative bioavailability and effect studies on metoprolol administered as ordinary and slow-release tablets in single and multiple doses.

Authors:  C G Regårdh; G Johnsson; L Jordö; L Sölvell
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

Review 5.  The assessment of beta-adrenoceptor blocking drugs in man.

Authors:  D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1977-08       Impact factor: 4.335

6.  Beta-blockers: once or three times a day?

Authors:  T Reybrouck; A Amery; R Fagard; P Jousten; P Lijnen; E Meulepas
Journal:  Br Med J       Date:  1978-05-27

7.  A comparison of slow release with conventional oxprenolol: plasma concentrations and clinical effects.

Authors:  M J West; M J Kendall; M Mitchard; E B Faragher
Journal:  Br J Clin Pharmacol       Date:  1976-06       Impact factor: 4.335

8.  Pharmacokinetic and pharmacodynamic studies with long-acting propranolol.

Authors:  J McAinsh; N S Baber; R Smith; J Young
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

9.  Kinetics of pharmacologic effects.

Authors:  G Levy
Journal:  Clin Pharmacol Ther       Date:  1966 May-Jun       Impact factor: 6.875

10.  Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker.

Authors:  H C Brown; S G Carruthers; G D Johnston; J G Kelly; J McAinsh; D G McDevitt; R G Shanks
Journal:  Clin Pharmacol Ther       Date:  1976-11       Impact factor: 6.875

View more
  14 in total

1.  Three times daily or 8-hourly.

Authors:  R Nigam; B J Loveday; S L Grainger; D G Maxton
Journal:  J R Soc Med       Date:  1986-01       Impact factor: 5.344

2.  Lack of evidence for polymorphism in metoprolol metabolism.

Authors:  D B Jack; M Wilkins; C P Quarterman
Journal:  Br J Clin Pharmacol       Date:  1983-08       Impact factor: 4.335

3.  Osmotically controlled-delivery of metoprolol in man: in vivo performance of Oros systems with different durations of drug release.

Authors:  J Godbillon; A Gerardin; J Richard; D Leroy; J Moppert
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

4.  A single and multiple dose pharmacokinetic and pharmacodynamic comparison of conventional and slow-release metroprolol.

Authors:  M J Kendall; V A John; C P Quarterman; P G Welling
Journal:  Eur J Clin Pharmacol       Date:  1980-02       Impact factor: 2.953

5.  Comparison of the duration of effect of metoprolol and a sustained release formulation of metoprolol (betaloc-SA).

Authors:  D W Harron; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1981-05       Impact factor: 4.335

6.  Maximal exercise power after a single dose of metoprolol and of slow-release metoprolol.

Authors:  H Folgering; M van Bussel
Journal:  Eur J Clin Pharmacol       Date:  1980-10       Impact factor: 2.953

7.  Metabolic aspects of maximal exercise performance after slow release metoprolol and after atenolol.

Authors:  H T Folgering; J F Borm; R H van Haaren
Journal:  Eur J Clin Pharmacol       Date:  1982-10       Impact factor: 2.953

8.  Comparative pharmacological and pharmacokinetic observations on propranolol (long acting formulation) and bendrofluazide administered separately and concurrently to volunteers.

Authors:  D P Nicholls; D W Harron; J McAinsh; W M Castle; N P Barker; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

9.  Osmotic delivery systems for the beta-adrenoceptor antagonists metoprolol and oxprenolol: design and evaluation of systems for once-daily administration.

Authors:  F Theeuwes; D R Swanson; G Guittard; A Ayer; S Khanna
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

10.  Oros controlled-release formulations of metoprolol: an approach to the development of a system for once daily administration.

Authors:  W Good; L J Leeson; S L Zak; W E Wagner; J B Meeker; J D Arnold
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.